News Brolucizumab as Good as Aflibercept for Neovascular AMD by Medscape • 2019/06/04 • 0 Comments Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials. Reuters Health Information Full Story →